扁平上皮非小細胞肺癌(Squamous Non-Small Cell Lung Cancer):治療薬開発パイプライン動向(世界、2015年上半期版)

Global Markets Directが発行した調査報告書(GMDHC6161IDB)
◆英語タイトル:Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2015
◆商品コード:GMDHC6161IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2015年1月30日
◆ページ数:154
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における扁平上皮非小細胞肺癌(Squamous Non-Small Cell Lung Cancer)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・扁平上皮非小細胞肺癌(Squamous Non-Small Cell Lung Cancer)の概要
・扁平上皮非小細胞肺癌(Squamous Non-Small Cell Lung Cancer)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・扁平上皮非小細胞肺癌(Squamous Non-Small Cell Lung Cancer)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・扁平上皮非小細胞肺癌(Squamous Non-Small Cell Lung Cancer)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・扁平上皮非小細胞肺癌(Squamous Non-Small Cell Lung Cancer)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Squamous Non-Small Cell Lung Cancer – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Squamous Non-Small Cell Lung Cancer – Pipeline Review, H1 2015’, provides an overview of the Squamous Non-Small Cell Lung Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Squamous Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Squamous Non-Small Cell Lung Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Squamous Non-Small Cell Lung Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Squamous Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Squamous Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Squamous Non-Small Cell Lung Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Squamous Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Squamous Non-Small Cell Lung Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Squamous Non-Small Cell Lung Cancer – Overview 10
Pipeline Products for Squamous Non-Small Cell Lung Cancer – Comparative Analysis 11
Squamous Non-Small Cell Lung Cancer – Therapeutics under Development by Companies 12
Squamous Non-Small Cell Lung Cancer – Therapeutics under Investigation by Universities/Institutes 15
Squamous Non-Small Cell Lung Cancer – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Squamous Non-Small Cell Lung Cancer – Products under Development by Companies 19
Squamous Non-Small Cell Lung Cancer – Products under Investigation by Universities/Institutes 21
Squamous Non-Small Cell Lung Cancer – Companies Involved in Therapeutics Development 22
AbbVie Inc. 22
Advenchen Laboratories, LLC 23
Ascenta Therapeutics, Inc. 24
AstraZeneca PLC 25
Bayer AG 26
Boehringer Ingelheim GmbH 27
Bristol-Myers Squibb Company 28
Celgene Corporation 29
Eisai Co., Ltd. 30
Eli Lilly and Company 31
F. Hoffmann-La Roche Ltd. 32
Five Prime Therapeutics, Inc. 33
Genentech, Inc. 34
Johnson & Johnson 35
Novartis AG 36
Oncogenex Pharmaceuticals, Inc. 37
Ono Pharmaceutical Co., Ltd. 38
Vertex Pharmaceuticals Incorporated 39
Squamous Non-Small Cell Lung Cancer – Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Target 41
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
ABT-414 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
apatorsen – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AT-406 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AZD-8186 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
BAY-1163877 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BMS-833923 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
BMS-906024 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
buparlisib hydrochloride – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
FP-1039 – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ipilimumab – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
JNJ-42756493 – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
lenvatinib – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
lucitanib – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
lumretuzumab – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
LY-2606368 – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
LY-3023414 – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
necitumumab – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
nintedanib – Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
nivolumab (recombinant) – Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
paclitaxel albumin bound – Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
pictilisib – Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Small Molecule to Inhibit TWIST1 for Non-Small Cell Lung Cancer – Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
veliparib – Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
VX-970 – Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Squamous Non-Small Cell Lung Cancer – Recent Pipeline Updates 109
Squamous Non-Small Cell Lung Cancer – Dormant Projects 145
Squamous Non-Small Cell Lung Cancer – Discontinued Products 146
Squamous Non-Small Cell Lung Cancer – Product Development Milestones 147
Featured News & Press Releases 147
Jan 11, 2015: CheckMate -017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-small Cell Lung Cancer, Stopped Early 147
Oct 30, 2014: Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology 147
Oct 23, 2014: Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer 149
Jul 01, 2014: OncoGenex Announces Cedar Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment 150
May 14, 2014: Clovis Oncology Announces Clinical Data Of Lucitanib to Be Presented at 2014 ASCO Annual Meeting 150
Aug 13, 2013: Eli Lilly and Company’s Phase III study of necitumumab meets primary endpoint 151
Jun 04, 2013: Debiopharm Announces Additional Phase I Clinical Trial Evaluating Debio 1143 Combined With Chemotherapies For Patients With Selected Solid Malignancies 151
May 23, 2013: OncoGenex Pharma Announces Plans For Initiation Of Cedar Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer 152
Appendix 153
Methodology 153
Coverage 153
Secondary Research 153
Primary Research 153
Expert Panel Validation 153
Contact Us 154
Disclaimer 154

[List of Tables]
Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H1 2015 10
Number of Products under Development for Squamous Non-Small Cell Lung Cancer - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Squamous Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc., H1 2015 22
Squamous Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015 23
Squamous Non-Small Cell Lung Cancer - Pipeline by Ascenta Therapeutics, Inc., H1 2015 24
Squamous Non-Small Cell Lung Cancer - Pipeline by AstraZeneca PLC, H1 2015 25
Squamous Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H1 2015 26
Squamous Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 27
Squamous Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015 28
Squamous Non-Small Cell Lung Cancer - Pipeline by Celgene Corporation, H1 2015 29
Squamous Non-Small Cell Lung Cancer - Pipeline by Eisai Co., Ltd., H1 2015 30
Squamous Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2015 31
Squamous Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 32
Squamous Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics, Inc., H1 2015 33
Squamous Non-Small Cell Lung Cancer - Pipeline by Genentech, Inc., H1 2015 34
Squamous Non-Small Cell Lung Cancer - Pipeline by Johnson & Johnson, H1 2015 35
Squamous Non-Small Cell Lung Cancer - Pipeline by Novartis AG, H1 2015 36
Squamous Non-Small Cell Lung Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2015 37
Squamous Non-Small Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 38
Squamous Non-Small Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 39
Assessment by Monotherapy Products, H1 2015 40
Number of Products by Stage and Target, H1 2015 42
Number of Products by Stage and Mechanism of Action, H1 2015 45
Number of Products by Stage and Route of Administration, H1 2015 47
Number of Products by Stage and Molecule Type, H1 2015 49
Squamous Non-Small Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H1 2015 109
Squamous Non-Small Cell Lung Cancer - Dormant Projects, H1 2015 145
Squamous Non-Small Cell Lung Cancer - Discontinued Products, H1 2015 146

[List of Figures]
Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H1 2015 10
Number of Products under Development for Squamous Non-Small Cell Lung Cancer - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Assessment by Monotherapy Products, H1 2015 40
Number of Products by Top 10 Targets, H1 2015 41
Number of Products by Stage and Top 10 Targets, H1 2015 41
Number of Products by Top 10 Mechanism of Actions, H1 2015 44
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 44
Number of Products by Top 10 Routes of Administration, H1 2015 46
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 46
Number of Products by Top 10 Molecule Types, H1 2015 48
Number of Products by Stage and Top 10 Molecule Types, H1 2015 48

【掲載企業】

AbbVie Inc.
Advenchen Laboratories, LLC
Ascenta Therapeutics, Inc.
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Johnson & Johnson
Novartis AG
Oncogenex Pharmaceuticals, Inc.
Ono Pharmaceutical Co., Ltd.
Vertex Pharmaceuticals Incorporated

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 扁平上皮非小細胞肺癌(Squamous Non-Small Cell Lung Cancer):治療薬開発パイプライン動向(世界、2015年上半期版)(Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆